Browsing by Author "Pedrosa, Mariana Gaspar"
Now showing 1 - 1 of 1
Results Per Page
Sort Options
- Fosfomycin vs. Cefixime on infectious prophylaxis of transrectal prostatic biopsy: Prospective studyPublication . Pedrosa, Mariana Gaspar; Lourenço, Mário José Pereira; Pereira, Bruno Alexandre Guerra Jorge; Brito, Duarte Vaz Franco de Vieira eIntroduction: Antibiotic prophylaxis in transrectal prostatic biopsy is the key to controlling infectious complications. Our study aims to investigate the efficacy of fosfomycin versus cefixime as a single prophylactic treatment regimen. Material and Methods: This prospective randomized study included patients with a previous clinical suspicion of prostate cancer that were divided into two groups. Group 1 received oral fosfomycin 3g before and 24 hours after the biopsy. Group 2 was treated with cefixime 400mg orally for 3 days, starting the day before the procedure. A questionnaire quantified urinary symptoms and recorded clinical signs of infection. Urinary tract infection was defined by the presence of fever (temperature equal to or greater than 38ºC), diagnosis of infection by a healthcare professional, or antibiotic prescription. Logistic regression models studied the frequency of infection according to the antibiotic prophylaxis prescribed and patient- and procedure-related risk factors. Results: Of 118 patients, 50 (42.4%) received fosfomycin and 68 (57.6%) cefixime. The mean age was 68.7 years, and the median PSA value was 8 ng/ml. The overall incidence of urinary infection was 8.5% (12% in group 1 versus 5.9% in group 2; p=0.238). No baseline characteristics were significantly associated with infection. No need for hospital admission was documented. Cefixime was more associated with worsening urinary tract symptoms and quality of life after biopsy (group 1: -0,7; group 2: -1,5; p=0,347; group 1: -0,1; group 2: -0,4; p=0,059, respectively). Conclusion: Fosfomycin has shown similar efficacy to cefixime in preventing infectious complications resulting from transrectal prostate biopsy.